Skip to main content
SpringerLink
Log in

Defining Value: The Need for a Longer, Broader View

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Memorial Sloan Kettering Cancer Center. Drug abacus. http://www.drugabacus.org/. Accessed 18 Febr 2017.

  2. Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–34.

    Article  PubMed  Google Scholar 

  3. Burwell SM. Setting value-based payment goals: HHS efforts to improve U.S. health care. N Engl J Med. 2015;372(10):897–9.

    Article  CAS  PubMed  Google Scholar 

  4. Lichtenberg F, Philipson T. The dual effects of intellectual property regulations: within and between patent competition in the US Pharmaceutical Industry. J Law Econ. 2002;45(Suppl 2):643–72.

    Article  Google Scholar 

  5. Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E. Authorized generic drugs, price competition, and consumers’ welfare. Health Aff (Millwood). 2007;26(3):790–9.

    Article  PubMed  Google Scholar 

  6. Federal Trade Commission. Emerging health care issues: follow-on biologic drug competition. Federal trade commission report. June 2009. Washington, DC: Federal Trade Commission; 2009.

  7. Lu Y, Penrod JR, Sood N, Woodby S, Philipson T. Dynamic cost-effectiveness of oncology drugs. Am J Manage Care. 2012;18(11):S249–56.

    Google Scholar 

  8. Goldman D, Lakdawalla D, Baumgardner J, Linthicum M. Are biopharmaceutical budget caps good public policy? Econ Voice. 2016;13(1):27–42. doi:10.1515/ev-2014-0012.

    Google Scholar 

  9. Philipson TJ, Jena AB. Who benefits from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs. Forum Health Econ Policy. 2006;9(2):3. doi:10.2202/1558-9544.1005.

    Article  Google Scholar 

  10. Lakdawalla DN, Sun EC, Jena AB, Reyes CM, Goldman DP, Philipson TJ. An economic evaluation of the war on cancer. J Health Econ. 2010;29(3):333–46.

    Article  PubMed  Google Scholar 

  11. Antonanzas F, Terkola R, Postma M. The value of medicines: a crucial but vague concept. Pharmacoeconomics. 2016;34(12):1227–39.

    Article  PubMed  Google Scholar 

  12. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.

    Article  PubMed  Google Scholar 

  13. Kunkle F. Alzheimer’s caregivers likely to spend more than $50,000 a year. Washington Post. 30 September 2015.

  14. Grant M, Sun V, Fujinami R, et al. Family caregiver burden, skills preparedness, and quality of life in non-small cell lung cancer. Oncol Nurs Forum. 2013;40(4):337–46.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Gridelli C, Ferrara C, Guerriero C, et al. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. J Thorac Oncol. 2007;2(6):475–80.

    Article  PubMed  Google Scholar 

  16. Fujinami R, Sun V, Zachariah F, Uman G, Grant M, Ferrell B. Family caregivers’ distress levels related to quality of life, burden, and preparedness. Psychooncology. 2015;24(1):54–62.

    Article  PubMed  Google Scholar 

  17. Grunfeld E, Coyle D, Whelan T, et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ. 2004;170(12):1795–801.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hoefman RJ, Van Exel J, Brouwer WBF. Measuring care-related quality of life of caregivers for use in economic evaluations: carerqol tariffs for Australia, Germany, Sweden, UK, and US. Pharmacoeconomics. 2017;35(4):469–78.

  19. Krol M, Papenburg J, van Exel J. Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies. Pharmacoeconomics. 2015;33(2):123–35.

    Article  PubMed  Google Scholar 

  20. Elwert F, Christakis NA. The effect of widowhood on mortality by the causes of death of both spouses. Am J Public Health. 2008;98(11):2092–8.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Christakis NA, Allison PD. Mortality after the hospitalization of a spouse. N Engl J Med. 2006;354(7):719–30.

    Article  CAS  PubMed  Google Scholar 

  22. Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ. 2005;24(4):751–73.

    Article  PubMed  Google Scholar 

  23. Thornton Snider J, Romley JA, Vogt WB, Philipson TJ. The option value of innovation. Forum Health Econ Policy. 2012;15(2):18.

    Article  Google Scholar 

  24. Sanchez Y, Penrod JR, Qiu XL, Romley J, Thornton Snider J, Philipson T. The option value of innovative treatments in the context of chronic myeloid leukemia. Am J Manag Care. 2012;18(11 Suppl):S265–71.

    PubMed  Google Scholar 

  25. Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood). 2012;31(4):676–82.

    Article  PubMed  Google Scholar 

  26. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276(14):1172–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Irving B. Harris Graduate School of Public Policy Studies, University of Chicago, 1155 E. 60th Street, Chicago, IL, 60637, USA

    Tomas J. Philipson

  2. Innovation Center, Global Health and Value, Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA

    Sachin Kamal-Bahl

  3. Department of Health Care Policy, Harvard Medical School, Boston, MA, USA

    Anupam B. Jena

  4. Massachusetts General Hospital, Boston, MA, USA

    Anupam B. Jena

Authors
  1. Tomas J. Philipson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sachin Kamal-Bahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anupam B. Jena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomas J. Philipson.

Ethics declarations

Funding

Funding was provided by Pfizer, Inc., to Precision Health Economics (PHE) for the conduct of this research.

Conflict of interest

Dr Philipson is a cofounder of and consultant to PHE, a health economics consultancy to the life science industry. Dr Philipson holds stock in PHE’s parent company, Precision Medicine Group. Dr Kamal-Bahl is an employee and shareholder of Pfizer, Inc. Dr Jena is a consultant to PHE and reports receiving previous consulting fees unrelated to this work from Pfizer, Inc., Hill Rom Services, Inc., Bristol Myers Squibb, Novartis Pharmaceuticals, Vertex Pharmaceuticals and PHE.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Philipson, T.J., Kamal-Bahl, S. & Jena, A.B. Defining Value: The Need for a Longer, Broader View. PharmacoEconomics 35, 669–672 (2017). https://doi.org/10.1007/s40273-017-0503-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-017-0503-7

Keywords

Search

Navigation